In CML patients, bone marrow CD34+Lin- cells, in which normal hematopoietic stem cells (HSCs) reside, are thought to contain CML stem cells and be responsible for disease initiation, progression and resistance to imatinib [14, 15]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.